Aminoleban EN Mechanism of Action

Pharmacology: In experiments using rats and dogs with portacaval shunts (PCS) as a chronic hepatic insufficiency model, AMINOLEBAN EN powder normalized the imbalanced plasma and brain free amino acid concentration patterns, and in particular, improved abnormal intracerebral serotonin metabolism.
In experimental coma induced by loading ammonia on normal rats, AMINOLEBAN EN powder tended to prevent the onset of coma and to reduce the duration of coma. In ammonia-loaded PCS rats, AMINOLEBAN EN powder inhibited the decrease in electroencephalographic voltage.
In hepatic devascularized rats used as an acute hepatic insufficiency model, AMINOLEBAN EN powder improved plasma and brain free amino acid concentration imbalances and abnormal intracerebral amine metabolism.
In PCS rats used as a chronic hepatic insufficiency model, repeated administration of AMINOLEBAN EN powder increased body weight and produced a positive nitrogen balance. Also, the protein efficiency ratio tended to increase. In a postoperative injury catabolic state in the PCS rats, repeated administration of AMINOLEBAN EN powder increased body weight and produced a positive nitrogen balance. In rats with hepatic disorder induced by treatment with carbon tetrachloride, AMINOLEBAN EN powder suppressed the decrease in body weight and produced a positive nitrogen balance.
In rats with obstructive jaundice produced by ligation of the common bile duct, AMINOLEBAN EN powder increased body weight and produced a positive nitrogen balance.
Clinical Studies: Usefulness: The clinical dietary value of AMINOLEBAN EN powder was compared with that of a conventional liver diet alone in hepatic insufficiency patients, mostly those with hepatic encephalopathy. Usefulness was assessed based on global improvement of EEG findings, neuropsychiatric symptoms, subjective and objective symptoms and Fischer's ratio, and safety. According to the results, AMINOLEBAN EN powder was determined to be useful in 65.5% (74 of 113) of the patients studied.
In a long-term study with AMINOLEBAN EN powder using decompensated cirrhosis patients, usefulness was assessed based on the quality of life, including coma scale, Karnofsky's performance score and change in patient status from inpatient to outpatient. Usefulness was demonstrated in 72.9% (70 of 96) of the patients studied.
Effect on Patient Survival: The cumulative survival rate in the patients treated with AMINOLEBAN EN powder for 6 month was significantly greater than that in the patients of historical data group.
Nutritional Improvement: AMINOLEBAN EN powder produced a positive nitrogen balance and improved serum protein levels.